Eva Selhub
About Eva Selhub, M.D.
Independent director at MariMed Inc. since September 2019; age 57 as of the 2025 proxy. Board-certified physician, speaker, scientist, executive leadership/performance coach, consultant in corporate wellness/resilience, and author. Education: B.A. in anthropology from Tufts University (1989) and M.D. from Boston University School of Medicine (1994). Prior academic roles include instructor/lecturer at Harvard Medical School (1997–2016), senior physician at the Benson Henry Institute for Mind/Body Medicine at Massachusetts General Hospital (2006–2017), and adjunct scientist of neuroscience at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (2016–2021) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Harvard Medical School | Instructor and Lecturer of Medicine | 1997–2016 | Academic and clinical teaching |
| Benson Henry Institute, MGH | Senior Physician (Mind/Body Medicine) | 2006–2017 | Mind-body clinical practice |
| Tufts Univ. — USDA HNRCA | Adjunct Scientist (Neuroscience) | 2016–2021 | Research in nutrition/aging neuroscience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Self-employed/Independent | Executive leadership and performance coach; corporate wellness/resilience consultant; author | Ongoing | Board-certified physician, speaker, scientist |
Board Governance
- Independence: Board determined Dr. Selhub is independent under Nasdaq standards .
- Committee assignments and chair roles:
- 2025: Nominating & Governance Committee — Chair; Compensation Committee — Member; Audit Committee — Not a member .
- 2024: Nominating & Governance Committee — Chair; Compensation Committee — Not a member; Audit Committee — Not a member .
- Attendance and engagement: In FY2024, Board held 6 meetings; Audit 5; Compensation 3; Nominating & Governance 1. All directors attended or participated in at least 75% of meetings of the Board and committees on which they served; directors were encouraged to attend the annual meeting and those serving at the time did attend in 2024 .
- Board leadership: Independent, non-executive Chairman (Edward Gildea); separation of Chair and CEO roles emphasized for independence and oversight .
- Trading policy: Prohibits trading on MNPI and hedging (short sales, puts, calls); pre-approval required for trades by directors .
| Committee | 2024 Membership | Chair (2024) | 2025 Membership | Chair (2025) |
|---|---|---|---|---|
| Audit | Allen, Gildea, Tucker | Allen | Allen, Gildea | Allen |
| Compensation | Allen, Gildea, Tucker | Tucker | Allen, Gildea, Selhub | Gildea |
| Nominating & Governance | Allen, Gildea, Selhub | Selhub | Allen, Gildea, Selhub | Selhub |
Fixed Compensation
- Structure: Annual retainer $40,000; RSU grant of 75,000 annually (vests one year from grant); Chair stipends — Chairman $10,000, Audit Chair $7,500, Compensation Chair $5,000, Nominating & Governance Chair $5,000 .
- Change: In 2023, Board increased annual retainer from $25,000 to $40,000 and annual RSU grant to 75,000; added chair stipends; special one-time 2023 stipends of $25,000 only for Allen and Tucker (not Selhub) .
| Year | Cash Fees (USD) | Stock Awards Grant-Date FV (USD) | Total (USD) | Notes |
|---|---|---|---|---|
| 2023 | $40,000 | $30,375 | $70,375 | RSUs: 75,000 granted 6/8/2023; vests 1 year |
| 2024 | $45,000 | $15,750 | $60,750 | RSUs: 75,000 granted 6/6/2024; vests 1 year |
Performance Compensation
- Director equity grants: Annual RSUs vest time-based after one year; no performance metrics disclosed for director equity (RSUs convert one-for-one to common shares) .
| Equity Award | Grant Date | Shares/Units | Vesting Schedule | Performance Metrics |
|---|---|---|---|---|
| RSU (Director Annual) | 6/8/2023 | 75,000 | Vests in full on 6/8/2024 | None disclosed |
| RSU (Director Annual) | 6/6/2024 | 75,000 | Vests in full on 6/6/2025 | None disclosed |
Clawback policy: Awards under the 2018 Plan are subject to the Company’s clawback policy in effect at grant .
Other Directorships & Interlocks
| Company | Role | Committee Roles | Status |
|---|---|---|---|
| None disclosed | — | — | No other public company directorships disclosed in the proxy biographies |
Expertise & Qualifications
- Health and wellness expertise (mind-body medicine), leadership/performance coaching, and resilience — relevant to human capital, culture, and governance oversight .
- Independent governance leadership through chairing Nominating & Governance Committee; not designated audit financial expert (that role is held by David Allen) .
Equity Ownership
| As-of Date | Beneficial Ownership (Shares) | % of Outstanding | Components/Notes |
|---|---|---|---|
| Record Date 4/15/2024 | 308,333 | <1% | Includes 200,000 options and 75,000 RSUs subject to vesting |
| Record Date 4/15/2025 | 283,333 | <1% | Includes 100,000 options and 75,000 RSUs subject to vesting |
| Instrument | Quantity | Terms |
|---|---|---|
| Stock Options | 200,000 (2023 YE) | 100,000 expire 9/27/2024; 100,000 expire 7/9/2026 |
| Stock Options | 100,000 (2024 YE) | Expire 7/9/2026 |
| Unvested RSUs | 75,000 (2023 grant) | Vested 6/8/2024 |
| Unvested RSUs | 75,000 (2024 grant) | Vest 6/6/2025 |
- Hedging/pledging: Hedging prohibited by insider trading policy; no pledging disclosures specific to directors; none indicated for Dr. Selhub .
Related-Party Exposure and Conflicts
- No related-party transactions involving Dr. Selhub disclosed in the 2024–2025 proxies .
- Company-level related-party transactions primarily involve the CEO and COO (HQ lease with CEO interest; purchases from family-owned entity of COO; royalty agreements tied to product IP held by COO and Chief Commercial Officer; subsidiary distributions to CEO; guarantees by CEO) — Audit Committee reviews and approves related-party transactions per charter .
Governance Assessment
- Strengths:
- Independent director with stable tenure since 2019; chairs Nominating & Governance, signaling trust in her governance oversight .
- Attendance threshold met; Board maintains independent chair and clear committee structure; trading policy prohibits hedging .
- Director pay modest, predominantly cash retainer and time-based RSUs; equity under clawback policy .
- Watch items:
- Heavy related-party transactions at the company level demand robust Audit oversight; Dr. Selhub is not on the Audit Committee, so her conflict oversight influence is via Nominating & Governance and Compensation .
- No disclosed director stock ownership guidelines or performance conditions for director equity; ownership remains <1%, potentially limiting alignment signals versus best-practice guidelines .
- Committee reconfiguration in 2025 places her on Compensation; monitor pay decisions for independence and consultant conflicts (none disclosed) .
RED FLAGS (Company-level context, not attributed to Dr. Selhub): Related-party purchases and royalties tied to executives; personal guarantees by CEO; ongoing lease with CEO interest — require vigilant Audit Committee monitoring .